Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Longitude Prize

- PMLiVE

Bristol Myers Squibb announces positive trial results for treatment of MS

In the two phase 3 trials, Zeposia treatment showed improved or preserved cognitive function in the majority of patients

- PMLiVE

Six UK universities receive grant for research into motor neurone disease

The grant was given by the Medical Research Council and the National Institute for Health and Care Research, along with charities LifeArc, MND Association, My Name’5 Doddie Foundation and MND...

- PMLiVE

Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease

The new approach would allow doctors to identify the disease at an early stage and provide treatment and support to patients sooner

- PMLiVE

LifeArc partners with UK Dementia Research Institute

Dementia affects around 900,000 people in the UK and this is expected to rise to around 1.6 million by 2040

- PMLiVE

TauRx shares phase 3 trial data for Alzheimer’s drug

Those receiving the drug experienced a significantly slower decline than usual

- PMLiVE

The Michael J Fox Foundation gives Asceneuron second research grant

Parkinson's disease affects an estimated seven to ten million people worldwide

- PMLiVE

BioXcel Therapeutics begins phase 3 trial for acute agitation in Alzheimer’s patients

There are no approved treatment options available for acute agitation related to dementia

- PMLiVE

Longitude Prize in final stage of deciding recipients of £8m prize

The prize will be awarded to a team of innovators who develop a point-of-care diagnostic test that will help combat antimicrobial-resistant infections

- PMLiVE

Muna raises $73m to advance neurodegenerative disease-focused small molecule pipeline

The company is focused on developing investigational new drug applications for diseases including Alzheimer’s and Parkinson’s

- PMLiVE

GlaxoSmithKline agrees $2.2bn dementia mAb deal with Alector

The focus of the deal is two clinical-stage monoclonal antibodies in development for a number of neurodegenerative diseases

- PMLiVE

Alzheimer’s disease: the search for a cure

To ensure the successful discovery and development of new dementia therapies, key gaps in the field need to be addressed

- PMLiVE

Merck & Co signs deal with Amathus for neurodegenerative diseases

Collaboration will focus on developing small molecules for undisclosed disease targets

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links